105191-12-6

Basic information

• Product Name: 6-BROMO-1H-INDOLE-2-CARBALDEHYDE
• Synonyms: 6-BROMO-1H-INDOLE-2-CARBALDEHYDE;6-Bromo-1H-indole-2-carbaldehyde ,97%;6-BroMo-1H-indol-2-carbaldehyde;6-Bromo-2-formyl-1H-indole
• CAS NO: 105191-12-6
• Molecular Formula: C₉H₆BrNO
• Molecular Weight: 224.05
• Mol File: 105191-12-6.mol
• Article Data: 8

Chemical Properties

• Melting Point: 181-183°
• Boiling Point: 395.55 °C at 760 mmHg
• Flash Point: 193.022 °C
• Appearance: /
• Density: 1.727 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.752
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 14.12±0.30(Predicted)
• CAS DataBase Reference: 6-BROMO-1H-INDOLE-2-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-1H-INDOLE-2-CARBALDEHYDE(105191-12-6)
• EPA Substance Registry System: 6-BROMO-1H-INDOLE-2-CARBALDEHYDE(105191-12-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36-36/37/38
• Safety Statements: 26-36/37
• HazardClass: IRRITANT
• Hazardous Substances Data: 105191-12-6(Hazardous Substances Data)

Usage

Chemical Properties

White to yellow solid

Uses

6-Bromo-1H-indole-2-carbaldehyde is used as a reactant in the optimization of bis-indole pyruvate kinase inhibitors as potential therapeutics for the methicillin-resistant Staphylococcus aureus infection treatment.

InChI:InChI=1/C9H6BrNO/c10-7-2-1-6-3-8(5-12)11-9(6)4-7/h1-5,11H

Upstream product

• 103858-53-3 ethyl 6-bromo-1H-indole-2-carboxylate 
• 372089-59-3 6-bromoindole 2-carboxylic acid methyl ester 
• 16732-65-3 6-bromo-indole-2-carboxylic acid(Ref_.7.) 
• 923197-75-5 (6-bromo-1H-indol-2-yl)methanol 

Downstream Products

• 1382774-46-0 4-(4-fluorophenethyl)-1-(1,1,5-trimethyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-7-yl)piperazin-2-one 
• 1382774-64-2 tert-Butyl 7-(4-(4-fluorophenethyl)-2-oxopiperazin-1-yl)-1,1,5-trimethyl-3,4-dihydro-1H-pyrido[4,3-b]indole-2(5H)-carboxylate 
• 1382774-60-8 6-bromo-1-methyl-1H-indole-2-carbaldehyde 
• 105190-94-1 2-<2-(6-Amidinoindol-2-yl)-(E)-vinyl>-1-benzofuran-5-carboxamidin-dihydrochlorid 

Relevant articles and documents

Inhibition of 5-oxo-6,8,11,14-eicosatetraenoic acid-induced activation of neutrophils and eosinophils by novel indole oxe receptor antagonists

5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is a 5-lipoxygenase product that is a potent granulocyte chemoattractant, which induces the infiltration of eosinophils into human skin when injected intradermally. It could therefore be an important proinflammatory mediator in eosinophilic diseases such as asthma and allergic rhinitis, and the OXE receptor, which mediates its actions, is therefore an attractive drug target. Using a structure-based approach in which substituents mimicking the essential polar (C1-C5) and hydrophobic (C15-C20) regions of 5-oxo-ETE were incorporated on an indole scaffold, we identified two potent selective OXE antagonists with IC50 values of about 30 nM. Neither compound displayed agonist activity and both inhibited 5-oxo-ETE-induced chemotaxis and actin polymerization and were relatively resistant to metabolism by rat liver homogenates. The active enantiomers of these racemic antagonists were even more potent, with IC50 values of 10 nM. These selective OXE antagonists could potentially be useful therapeutic agents in allergic diseases such as asthma.

Amide-Amine Replacement in Indole-2-carboxamides Yields Potent Mycobactericidal Agents with Improved Water Solubility

Indolecarboxamides are potent but poorly soluble mycobactericidal agents. Here we found that modifying the incipient scaffold by amide-amine substitution and replacing the indole ring with benzothiophene or benzoselenophene led to striking (10-20-fold) im

THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION

Disclosed herein are compounds of formula (I), or a salt thereof and compositions comprising compounds of formula I that exhibit antibacterial activities, when tested alone and/or in combination with a bacterial efflux pump inhibitor. Also disclosed are methods of treating or preventing a bacterial infection in an animal comprising administering to the animal a compound of formula I alone or in combination with the administration of a bacterial efflux pump inhibitor.